ClinicalTrials.gg
Sign In
Status unknownNCT05849987Updated May 9, 2023

In Depth Observational Clinical Trial Of Retinitis Pigmentosa Patients

An observational study in Retinitis Pigmentosa, sponsored by Power Life Sciences Inc.. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Power Life Sciences Inc. · Observational

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Typically, clinical research participation favors a specific demographic group, and little research exists on how trial attributes affect participation. As such, this study seeks to analyze data from different demographic groups and check for recurring trends that could provide valuable insights for future retinitis pigmentosa patients.

02

Conditions studied

  • Retinitis Pigmentosa

Browse trials for

Keywords

  • retinitis pigmentosa
03

In context

Retinitis Pigmentosa

273 studies on the registry are indexed under Retinitis Pigmentosa; 71 are open to participants now.

This study's planned enrollment of 500 is above the median of 52 across 84 observational studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 111 studies on the registry; 109 are open to participants now.

Browse Power Life Sciences Inc. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Retinitis Pigmentosa patients who are actively considering enrolling in an interventional clinical trial, but have not yet completed enrollment and registration.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is 18+ years old
  • Confirmed diagnosis of retinitis pigmentosa
  • Signed Written Informed Consent

Exclusion criteria

Exclusion Criteria:

  • Inability to perform regular electronic reporting
  • Participant is actively receiving study therapy in another trial
  • Women of childbearing potential without a negative pregnancy test; or women who are lactating.
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patient decides to enroll in clinical trial

    Time frame: 3 months

  2. Rate of patients who remain in clinical trial to trial completion

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Miura G, Sugawara T, Kawasaki Y, Tatsumi T, Nizawa T, Baba T, Hanaoka H, Yamamoto S. Clinical Trial to Evaluate Safety and Efficacy of Transdermal Electrical Stimulation on Visual Functions of Patients with Retinitis Pigmentosa. Sci Rep. 2019 Aug 12;9(1):11668. doi: 10.1038/s41598-019-48158-5. PubMed 31406205 ↗
  • Arslan U, Ozmert E, Demirel S, Ornek F, Sermet F. Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results. Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):893-908. doi: 10.1007/s00417-018-3953-5. Epub 2018 Mar 15. PubMed 29546474 ↗
  • Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004 Sep;122(9):1297-305. doi: 10.1001/archopht.122.9.1297. PubMed 15364708 ↗

Study documents

  • Informed consent form · Apr 28, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for May 2025, 12 months later.

Of 48 observational studies under Retinitis Pigmentosa, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 9, 2023
StartEst.
May 2024
Primary completionEst.
May 2025
CompletionEst.
May 2026
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05849987
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
May 9, 2023
Start date
May 2024 (estimated)
Primary completion
May 2025 (estimated)
Completion
May 2026 (estimated)
Last update
May 9, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
4159004227
Michael B Gill
study director · Power Life Sciences Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Retinitis Pigmentosa →

Other studies from this sponsor

Power Life Sciences Inc. →

Start the discussion